Pyrrolobenzodiazepine-antibody conjugates

Inventors: Patricius Hendrikus Cornelis Van Berkel (Epalinges, CH); Philip Wilson Howard (Cambridge, GB)

Assignee: MEDIMMUNE LIMITED

A61K47/6849 A61K31/5517 A61K45/06 A61K47/6803 C07K16/2803 C07K2317/56

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,771,775
App. No.: 16/934,319
Granted: Oct 3, 2023
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Conjugates of an antibody that binds to CD19 with PBD dimers.

Claims (26)

1. A method of treating lymphoma or leukemia comprising administering to a patient a conjugate of formula ConjA:

ConjB:

ConjC:

ConjD:

or ConjE:

wherein Ab is an antibody that binds to CD19, the antibody comprising a VH domain having the amino acid sequence according to SEQ ID NO. 2 and a VL domain having the amino acid sequence of SEQ ID NO. 8; and

wherein the drug loading is an integer from 1 to 8.

2. The method of claim 1 , wherein the antibody is an intact antibody.

3. The method of claim 1 , wherein the antibody is humanized, deimmunized or resurfaced.

4. The method of claim 1 , wherein the drug loading is 1, 2, 3, or 4.

5. The method of claim 1 , wherein the lymphoma is a non-Hodgkin Lymphoma.

6. The method of claim 5 , wherein the non-Hodgkin Lymphoma is selected from the group consisting of: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Mantle Cell lymphoma (MCL) and chronic lymphatic lymphoma (CLL).

7. The method of claim 6 , wherein the non-Hodgkin Lymphoma is diffuse large B-cell lymphoma (DLBCL).

8. The method of claim 6 , wherein the non-Hodgkin Lymphoma is Mantle Cell lymphoma (MCL).

9. The method of claim 6 , wherein the non-Hodgkin Lymphoma is follicular lymphoma (FL).

10. The method of claim 1 , wherein the leukemia is selected from the group consisting of: Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v) and Acute Lymphoblastic Leukemia (ALL).

11. The method of claim 1 , wherein the conjugate is of formula ConjE:

12. The method of claim 11 , wherein the lymphoma is a non-Hodgkin Lymphoma.

13. The method of claim 12 , wherein the non-Hodgkin Lymphoma is selected from the group consisting of: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Mantle Cell lymphoma (MCL) and chronic lymphatic lymphoma (CLL).

14. The method of claim 13 , wherein the non-Hodgkin Lymphoma is diffuse large B-cell lymphoma (DLBCL).

15. The method of claim 13 , wherein the non-Hodgkin Lymphoma is Mantle Cell lymphoma (MCL).

16. The method of claim 13 , wherein the non-Hodgkin Lymphoma is follicular lymphoma (FL).

17. The method of claim 11 , wherein the leukemia is selected from the group consisting of: Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v) and Acute Lymphoblastic Leukemia (ALL).

18. The method of claim 11 , wherein the patient is administered a chemotherapeutic agent in combination with the conjugate.

19. The method of claim 18 , wherein the chemotherapeutic agent is a kinase inhibitor.

20. The method of claim 18 , wherein the chemotherapeutic agent is rituximab.

Assignments (6)

PATENT SECURITY AGREEMENT Recorded Jul 7, 2025

From: ADC THERAPEUTICS SA

To: BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.)

Reel/Frame 071832/0069 →

PATENT SECURITY AGREEMENT Recorded Dec 27, 2022

From: ADC THERAPEUTICS SA

To: OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.

Reel/Frame 062228/0763 →